Realm Therapeutics PLC Cancellation of AIM Listing (9555T)
March 26 2019 - 3:01AM
UK Regulatory
TIDMRLM
RNS Number : 9555T
Realm Therapeutics PLC
26 March 2019
Realm Therapeutics plc
("Realm", "Realm Therapeutics" or the "Company")
Cancellation of AIM Listing
MALVERN, PA, March 26, 2019 - Realm Therapeutics plc (NASDAQ:
RLM / AIM: RLM), a biopharmaceutical company with a proprietary
technology platform of stabilized high concentration HOCl,
announced on March 15, 2019 that the listing of the Company's
Ordinary Shares on AIM will cease and cancellation will be
effective from 7:00 a.m. (GMT) on March 27, 2019.
Accordingly, today will be the last day of trading of Realm's
Ordinary Shares on AIM. Information on how to convert Ordinary
Shares to American Depositary Shares ("ADSs") is available on the
Company's website at www.realmtx.com.
With effect from March 27, 2019, on the basis that the Company's
place of central management and control is outside of the UK,
Channel Islands and the Isle of Man, whilst the sale process
continues, the Takeover Code will no longer apply to the Company
and the process will no longer be a "formal process" under the
Takeover Code.
Capitalized terms used but not defined in this announcement
shall have the meanings given to them in the circular sent to Realm
shareholders on 15 February 2019, which remains available on the
Company's website at www.realmtx.com.
RNS-RLM
About Realm Therapeutics
For more information on Realm Therapeutics, please visit
www.realmtx.com.
Forward-Looking Statements
Certain statements contained herein constitute forward-looking
statements. These forward-looking statements reflect the Company's
judgment at the date of this announcement and are not intended to
give any assurance as to future results. Except as required by the
FCA, the London Stock Exchange, the Panel on Takeovers and Mergers,
the AIM Rules for Companies or applicable law, the Company
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained in this announcement to reflect any changes in the
Company's expectations about them or any changes in events,
conditions or circumstances on which any such statement is
based.
Contacts:
Realm Therapeutics plc
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating
Officer
Outside U.S.: +44 (0) 20 3727 1000
U.S.: +1 212 600 1902
Argot Partners
Stephanie Marks / Claudia Styslinger
+1 212 600 1902
FTI Consulting
Simon Conway
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer
+44 (0) 20 7496 3000
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLELLLKXFZBBZ
(END) Dow Jones Newswires
March 26, 2019 03:01 ET (07:01 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Sep 2023 to Sep 2024